Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
Gardie B, Remenieras A, Kattygnarath D, Bombled J, Lefèvre S, Perrier-Trudova V, Rustin P, Barrois M, Slama A, Avril MF, Bessis D, Caron O, Caux F, Collignon P, Coupier I, Cremin C, Dollfus H, Dugast C, Escudier B, Faivre L, Field M, Gilbert-Dussardier B, Janin N, Leport Y, Leroux D, Lipsker D, Malthieu F, McGilliwray B, Maugard C, Méjean A, Mortemousque I, Plessis G, Poppe B, Pruvost-Balland C, Rooker S, Roume J, Soufir N, Steinraths M, Tan MH, Théodore C, Thomas L, Vabres P, Van Glabeke E, Meric JB, Verkarre V, Lenoir G, Joulin V, Deveaux S, Cusin V, Feunteun J, Teh BT, Bressac-de Paillerets B, Richard S; French National Cancer Institute "Inherited predisposition to kidney cancer" network. Gardie B, et al. Among authors: meric jb. J Med Genet. 2011 Apr;48(4):226-34. doi: 10.1136/jmg.2010.085068. Epub 2011 Mar 12. J Med Genet. 2011. PMID: 21398687 Free article.
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WEE. Gauler TC, et al. Among authors: meric jb. Ann Oncol. 2012 Mar;23(3):678-687. doi: 10.1093/annonc/mdr255. Epub 2011 May 26. Ann Oncol. 2012. PMID: 21617019 Free article. Clinical Trial.
[Angiogenesis and renal cell carcinoma].
Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O. Billemont B, et al. Among authors: meric jb. Bull Cancer. 2007 Jul;94 Spec No:S232-40. Bull Cancer. 2007. PMID: 17846009 Review. French.
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O. Fruehauf J, et al. Among authors: meric jb. Clin Cancer Res. 2011 Dec 1;17(23):7462-9. doi: 10.1158/1078-0432.CCR-11-0534. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976544 Clinical Trial.
Biochemotherapy for advanced melanoma: maybe it is real.
Khayat D, Bernard-Marty C, Meric JB, Rixe O. Khayat D, et al. Among authors: meric jb. J Clin Oncol. 2002 May 15;20(10):2411-4. doi: 10.1200/JCO.2002.20.10.2411. J Clin Oncol. 2002. PMID: 12011117 No abstract available.
Metastatic malignant melanoma.
Meric JB, Rixe O, Khayat D. Meric JB, et al. Drugs Today (Barc). 2003;39 Suppl C:17-38. Drugs Today (Barc). 2003. PMID: 14988744 Review.
Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Méric JB, et al. Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64. doi: 10.1016/j.critrevonc.2006.01.003. Epub 2006 Mar 13. Crit Rev Oncol Hematol. 2006. PMID: 16531064 Review.
36 results